HemoCue wins patent infringement suit

For more than two years, HemoCue AB and EKF-diagnostics GmbH, a company in Magdeburg, Germany, have been involved in a patent infringement suit.

The patent in dispute is licensed to HemoCue AB, a pioneer in point-of-care testing. The Dusseldorf District Court where the German patent infringement case has been tried, announced its ruling on March 9. The Court found that the EKF product infringes HemoCue's patent, registered in 1995. The product, with near worldwide patent protection, is a Swedish invention and an established standard in near-patient hemoglobin testing globally. From a single drop of capillary blood, the product determines the concentration of hemoglobin -- a test used to diagnose acute blood loss, detect anemia and screen blood donors.

According to HemoCue's CEO, Thomas Glanzmann, this is an important victory providing a decisive first instance ruling on an issue included also in other legal proceedings. The Court in Dusseldorf is one of the leading patent courts in Europe and considered one of the most experienced and proficient in this area.

HemoCue will initiate preliminary enforcement of the Court's decision. Once in place, no further sales or manufacturing of the infringing cuvette will be permissible.

"We spend a lot of time and money on protecting our proprietary rights and will continue to do so," says Clas Runnberg, responsible for legal processes at HemoCue. "For years, we are making considerable efforts in research and development of new products. These are based on our own innovations and involve unique technology, and that requires sizeable investments. Ensuring the best patent protection possible is therefore an obvious priority. The court ruling today shows that this protection, in spite of the long wait, has a value."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Key kinase involved in cell division linked to abnormal blood vessel growth in genetic disorder